About GENCYTE THERAPEUTICS INC
Gencyte Therapeutics is focused on developing next-generation Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy for precision cancer treatment, aiming to address the limitations of current CAR-T therapies such as high toxicity and limited efficacy with solid tumors.
Development of next-generation CAR-T immunotherapyPrecision targeting of cancer variantsResearch into less toxic cancer treatmentsFocus on expanding treatment options for solid tumors
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| PHASE I SBIR CONCEPT AWARD FOR LOGIC GATED MOLECULAR ADAPTOR SYSTEM FOR JMML TREATMENT | Department of Health and Human Services | $500K | |
| GENCYTE THERAPEUTICS, INC. PROPOSES DEVELOPING A SYNTHETIC NOTCH RECEPTOR (SYNNOTCH) CONTROLLED PRECISION MOLE | Department of Health and Human Services | $355K |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to GENCYTE THERAPEUTICS INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.